Cipla Launches HUENA®, India’s First Non-Antibiotic UTI Drug Kumar Jeetendra | September 8, 2025 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced the launch of Methenamine Hippurate, a non-antibiotic treatment for patients suffering from recurrent urinary tract infections (UTIs), under the brand name HUENA. This marks a significant step forward for Cipla in the fight against Anti-Microbial Resistance (AMR) and reinforces its commitment …
Enteromix: Russia’s mRNA Vaccine for Colon Cancer Kumar Jeetendra | September 7, 2025 The Eastern Economic Forum, which took place from September 3 to September 6, 2025, in Vladivostok and is known for its landmark announcements, heard for the first time about Russia’s mRNA-based cancer vaccine, Enteromix, from the Federal Medical and Biological Agency (FMBA) of Russia. As per the available information, the vaccine has passed the preclinical …
Unplugging the Brain:The Science and Myths of Dopamine Detox Kumar Jeetendra | September 1, 2025 These days with all of the distractions notification sounds bring, as well as streaming sites and social media, the world as a whole can feel overwhelming. This overwhelming feeling explains why the phrase “dopamine detox” has gained a foothold in both productivity and wellness circles. The idea has practical outcomes where the elimination of stimulating …
Cipla Invests in iCaltech to Boost Respiratory Portfolio Kumar Jeetendra | July 22, 2025 Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) announced today that it has signed definitive agreements for investment in Optionally Convertible Preference Shares of iCaltech Innovations Private Limited (hereafter referred to as “iCaltech”), subject to completion of certain conditions. Cipla Invests in iCaltech to Strengthen Respiratory Diagnostics Ecosystem in India …
Common side effects of lisdexamfetamine explained Kumar Jeetendra | July 4, 2025 Unlike other medications, Vyvanse (Lisdexamfetamine) is one of the most prescribed medications for Attention Deficit Disorder (ADD), Hyperactivity Disorder (ADHD) and binge eating disorder (BED). Due to the fact that it has a once-a-day dosing and gentler onset it is preferred by a lot of doctors and patients. But as with all medications it does carry …
How Kimchi Pharma Probiotics Can Help Your Gut Health Kumar Jeetendra | July 4, 2025 The intersection where ancient techniques of fermentation meet modern pharmaceutical technology. That is the goal of kimchi Pharma Probiotics, which aims to strengthen dietary supplements for gut health with rigorous scientific refinement inspired by Korea’s representative fermented dish. The increased consumption of processed foods, coupled with the stressed lifestyles of people, has emerged as a …
Alembic Gets USFDA Nod for Doxorubicin Liposome Injection Kumar Jeetendra | June 30, 2025 30th June, 2025 Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials. The approved ANDA is therapeutically equivalent …
What is Validation in Pharma and Why Does It Matter? Kumar Jeetendra | June 8, 2025 The world of pharmaceuticals encompasses a broad scope on law and ethics. The need for safety, effectiveness, and quality is not only vital, but a legal and ethical prerequisite. This is where ‘validation’ comes into play. But what validation means in the pharma world and why it’s important? What Validation Means Validation refers to having …
Cipla Achieves Water Positivity Milestone in India Operations Kumar Jeetendra | June 5, 2025 Mumbai, June 05, 2025: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it has been certified as a water positive organisation by Bureau Veritas (BVQi) for its India operations in line with its sustainability targets. This milestone reinforces Cipla’s focused efforts to be a responsible corporate citizen and limit …
Alembic Pharma Gets USFDA Nod for Amlodipine-Atorvastatin Tablets Kumar Jeetendra | May 23, 2025 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Amlodipine and Atorvastatin Tablets USP, 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 …
Alembic Pharma Gets USFDA Nod for Rivaroxaban Tablets Kumar Jeetendra | May 15, 2025 Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Xarelto Tablets, 2.5 …
Alembic Pharma Gets USFDA Approval for Divalproex Sodium Capsules, 125 mg Kumar Jeetendra | December 20, 2024 Alembic Pharmaceuticals Limited (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Divalproex Sodium Delayed-Release Capsules USP, 125 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Depakote Sprinkle Capsules, 125 mg, of AbbVie Inc. Alembic …
